Presented by: Jane Ann Wade, HT(ASCP)MLT, West Virginia University, Morgantown, WV
Recent advancements for improving outcomes in NSCLC include immunotherapy treatments developed through genetic testing. EGFR mutations have been identified as a significant cause of poor response in a subset of NSCLC patients. FDA testing methods are now available using formalin-fixed paraffin embedded tissue to identify these mutations, and other genetic aberrations. The EGFR pathway, angiogenesis, tyrosine-kinase inhibitors, and in-vitro testing on FFPE tissue will be discussed.
This webinar is part of the 2020 Laboratory Webinar Series. Laboratory Webinars are a great, inexpensive way to provide continuing education to a large number of employees. The cost for each session is the same regardless of the number of attendees.